Kiora Pharmaceuticals(KPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

KPRX Kiora Pharmaceuticals

Trading 05-03 12:10:26 EDT

0.5392

+0.0039

+0.73%

High0.5597	Low0.5130	Vol25.71K
Open0.5338	D1 Closing0.5353	Amplitude8.72%
Mkt Cap14.16M	Tradable Cap10.56M	Total Shares26.26M
T/O13.73K	T/O Rate0.13%	Tradable Shares19.58M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"KPRX","market":"US","secType":"STK","nameCN":"Kiora Pharmaceuticals","latestPrice":0.5392,"timestamp":1714751488730,"preClose":0.5353,"halted":0,"volume":25713,"delay":0,"floatShares":19579243,"shares":26256197,"eps":-2.694072,"marketStatus":"Trading","change":0.0039,"latestTime":"05-03 12:10:26 EDT","open":0.5338,"high":0.5597,"low":0.513,"amount":13728.9986586,"amplitude":0.087241,"askPrice":0.5393,"askSize":100,"bidPrice":0.5381,"bidSize":60,"shortable":3,"etf":0,"ttmEps":-2.694072,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1714766400000},"marketStatusCode":2,"adr":0,"listingDate":1438315200000,"exchange":"NASDAQ","adjPreClose":0.5353,"preHourTrading":{"tag":"盘前","latestPrice":0.5495,"preClose":0.5353,"latestTime":"09:06 EDT","volume":27,"amount":14.6709009,"timestamp":1714741561011},"postHourTrading":{"tag":"盘后","latestPrice":0.5426,"preClose":0.5426,"latestTime":"17:21 EDT","volume":965,"amount":523.609,"timestamp":1714684913288},"volumeRatio":0.608374},"requestUrl":"/m/hq/s/KPRX/tweets","defaultTab":"tweets","newsList":[{"id":"2432901660","title":"Kiora Pharmaceuticals Inc    expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2432901660","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2432901660?lang=en_us&edition=fundamental","pubTime":"2024-05-03 22:56","pubTimestamp":1714748203,"startTime":"0","endTime":"0","summary":"* Kiora Pharmaceuticals Inc     is expected to show no change in quarterly revenue when it reports  results on May 7 (estimated) for the period ending March 31 2024   *    * LSEG's mean analyst estima","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2426230642","title":"Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2426230642","media":"Newsfile","top":-1,"share":"https://ttm.financial/m/news/2426230642?lang=en_us&edition=fundamental","pubTime":"2024-04-11 19:00","pubTimestamp":1712833200,"startTime":"0","endTime":"0","summary":"Approval for the clinical validation study was recently granted. The validation work can now begin shortly and will be performed in collaboration with Professor Robert Casson, MBBS , M.Biostat, DPhil, FRANZCO, consultant ophthalmologist at the Royal Adelaide Hospital and hHad of Ophthalmology and Visual Science at Adelaide University. The goal is to work with IRD patients to refine and validate specific endpoints to objectively and reliably measure functional vision changes, providing a standard and acceptable assessment for global regulatory bodies.\"Our patient community is encouraged by the new technologies and treatments under development for Choroideremia,\" said Kathi Wagner, Executive Director of the CRF. \"Importantly, we also recognize that rigorous, standardized assessments of vision correlating to improvements in everyday life are required to bring these treatments to the marketplace. The CRF's contribution under this grant will help ensure appropriate tests are available for a","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/SOmQwh1prp40bq4i_L1bbg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/ca25ccd80ccf0b08a2bacaf1f493cd81","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/SOmQwh1prp40bq4i_L1bbg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/ca25ccd80ccf0b08a2bacaf1f493cd81"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kiora-pharmaceuticals-receives-grant-choroideremia-110000764.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kiora-pharmaceuticals-receives-grant-choroideremia-110000764.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2425562465","title":"Kiora Pharmaceuticals to Present at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2425562465","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2425562465?lang=en_us&edition=fundamental","pubTime":"2024-04-05 19:02","pubTimestamp":1712314920,"startTime":"0","endTime":"0","summary":"Encinitas, California--(Newsfile Corp. - April 5, 2024) - Kiora Pharmaceuticals (NASDAQ: KPRX) invites investors to view the Company's online presentations from two upcoming investor conferences.Kiora","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=23032368","is_publish_highlight":false,"gpt_icon":0},{"id":"2422161728","title":"Analysts Offer Insights on Healthcare Companies: Altimmune (ALT), Kiora Pharmaceuticals (KPRX) and Actinium Pharmaceuticals (ATNM)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422161728","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422161728?lang=en_us&edition=fundamental","pubTime":"2024-03-28 19:30","pubTimestamp":1711625415,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Altimmune (ALT – Research Report), Kiora Pharmaceuti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-altimmune-alt-kiora-pharmaceuticals-kprx-and-actinium-pharmaceuticals-atnm?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-altimmune-alt-kiora-pharmaceuticals-kprx-and-actinium-pharmaceuticals-atnm?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422165982","title":"Kiora Pharmaceuticals to Present Additional Data from Its ABACUS-1 Trial in Retinitis Pigmentosa at the ARVO 2024 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2422165982","media":"Newsfile","top":-1,"share":"https://ttm.financial/m/news/2422165982?lang=en_us&edition=fundamental","pubTime":"2024-03-28 18:45","pubTimestamp":1711622700,"startTime":"0","endTime":"0","summary":"Encinitas, California-- - Kiora Pharmaceuticals, Inc. ,  announced that additional data from the ABACUS-1 trial has been accepted for presentation at the Association for Research in Vision and Ophthalmology  meeting in Seattle, WA, May 5-9, 2024. The additional data includes quantitative evaluation of the functional MRI measures. Qualitative assessment of fMRI demonstrated reactivation of the regions of the brain responsible for vision in a time-dependent manner, consistent with other improvements in visual function.The presentation, titled, \"Synthetic phototransduction with a light-responsive molecule  in advanced retinitis pigmentosa: the ABACUS-1 phase I/II trial,\" will be presented by Professor Robert James Casson, DPhil, Head of Ophthalmology and Visual Science at Adelaide University. The ABACUS-1 study was a Phase I/II first-in-human clinical trial of the Company's molecular photoswitch, KIO-301, in patients with late-stage retinitis pigmentosa . Initial preliminary topline resul","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Wyfx7_frMNudhHSnPTkeDg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/cd4579ada7ca9217d55759925e5c096c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Wyfx7_frMNudhHSnPTkeDg--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/cd4579ada7ca9217d55759925e5c096c"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kiora-pharmaceuticals-present-additional-data-104500438.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kiora-pharmaceuticals-present-additional-data-104500438.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2422961922","title":"Analysts Offer Insights on Healthcare Companies: Kiora Pharmaceuticals (KPRX) and Genmab (GMAB)","url":"https://stock-news.laohu8.com/highlight/detail?id=2422961922","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2422961922?lang=en_us&edition=fundamental","pubTime":"2024-03-27 18:30","pubTimestamp":1711535440,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Kiora Pharmaceuticals (KPRX – Research Report) and G...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kiora-pharmaceuticals-kprx-and-genmab-gmab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-kiora-pharmaceuticals-kprx-and-genmab-gmab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2422103975","title":"Kiora Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2422103975","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422103975?lang=en_us&edition=fundamental","pubTime":"2024-03-25 21:32","pubTimestamp":1711373537,"startTime":"0","endTime":"0","summary":"* Kiora Pharmaceuticals Inc    reported a quarterly adjusted loss of 47 cents per share for the quarter ended in December, higher than the same quarter last year, when the company reported EPS of $-1.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422733517","title":"BRIEF-Kiora Pharmaceuticals Says Recent Strategic Partnership And Financing Expected To Fund Operations Through 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2422733517","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2422733517?lang=en_us&edition=fundamental","pubTime":"2024-03-25 21:26","pubTimestamp":1711373198,"startTime":"0","endTime":"0","summary":"March 25  - Kiora Pharmaceuticals Inc   :   * KIORA PHARMACEUTICALS INC - RECENT STRATEGIC PARTNERSHIP AND FINANCING EXPECTED TO FUND OPERATIONS THROUGH 2026   * KIORA PHARMACEUTICALS INC - CONTINUES TO ADVANCE PIPELINE OF TREATMENTS FOR RARE RETINAL DISEASESSource text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2422590765","title":"Kiora Pharmaceuticals reports FY results","url":"https://stock-news.laohu8.com/highlight/detail?id=2422590765","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2422590765?lang=en_us&edition=fundamental","pubTime":"2024-03-25 19:14","pubTimestamp":1711365297,"startTime":"0","endTime":"0","summary":"Kiora Pharmaceuticals press release  : FYnet loss was $12.5 million for 2023 compared to $13.6 million for 2022.Kiora ended the year with $2.5 million in cash and cash equivalents and $2.0 million in tax receivables.The Company's cash and cash equivalents as of March 24, 2024, exceeds $30 million and the Company believes this will fund operations through 2026.More on Kiora Pharmaceuticals  Kiora stock soars after hours on deal with Thea Open Innovation Seeking Alpha’s Quant Rating on Kiora Pharmaceuticals Historical earnings data for Kiora Pharmaceuticals Financial information for Kiora Pharmaceuticals","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4083239-kiora-pharmaceuticals-reports-fy-results","is_publish_highlight":false,"gpt_icon":0},{"id":"2422908015","title":"Kiora Pharma Reported Q4 Net Loss of $(2.3)M, Cash Balance of $2.5M","url":"https://stock-news.laohu8.com/highlight/detail?id=2422908015","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2422908015?lang=en_us&edition=fundamental","pubTime":"2024-03-25 19:07","pubTimestamp":1711364820,"startTime":"0","endTime":"0","summary":"Kiora Pharma Reported Q4 Net Loss of $(2.3)M, Cash Balance of $2.5M","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/03/37910163/kiora-pharma-reported-q4-net-loss-of-2-3-m-cash-balance-of-2-5m","is_publish_highlight":false,"gpt_icon":0},{"id":"2422517036","title":"Kiora Pharmaceuticals Reports 2023 Results; Continues to Advance Pipeline of Treatments for Rare Retinal Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2422517036","media":"Newsfile","top":-1,"share":"https://ttm.financial/m/news/2422517036?lang=en_us&edition=fundamental","pubTime":"2024-03-25 19:00","pubTimestamp":1711364400,"startTime":"0","endTime":"0","summary":"Recent Strategic Partnership and Financing Expected to Fund Operations Through 2026. \"Our greatest priorities this year are to advance KIO-301 and KIO-104 to assess their further potential to benefit patients,\" said Brian M. Strem, Ph.D., chief executive officer of Kiora. \"Both products are clinically validated drug candidates based on proprietary and innovative small molecules targeting rare retinal diseases with large unmet needs.\"The balance sheet provides us the financial ability to fund further development of KIO-104 for the treatment of posterior non-infectious uveitis. Because non-infectious uveitis can be sight threatening, there is a strong market need for new, steroid sparing therapeutic approaches. The active compound in KIO-104 is a highly potent, disease modifying anti-inflammatory agent belonging to a class of drugs helping hundreds of thousands of patients with systemic autoimmune diseases including multiple sclerosis and rheumatoid arthritis. By delivering KIO-104 direc","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/jFSO.hM_cq07.JYpYNMr.w--~B/aD0xODc7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/2b14a78bd74ac7d8260c3ff29c69a9f2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/jFSO.hM_cq07.JYpYNMr.w--~B/aD0xODc7dz01NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/newsfile_64/2b14a78bd74ac7d8260c3ff29c69a9f2"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/kiora-pharmaceuticals-reports-2023-results-110000804.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/kiora-pharmaceuticals-reports-2023-results-110000804.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2420229267","title":"Kiora Pharmaceuticals Inc    expected to post a loss of 42 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2420229267","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2420229267?lang=en_us&edition=fundamental","pubTime":"2024-03-19 20:55","pubTimestamp":1710852949,"startTime":"0","endTime":"0","summary":"* Kiora Pharmaceuticals Inc     is expected to show no change in quarterly revenue when it reports  results on March 21 (estimated) for the period ending December 31 2023   *    * LSEG's mean analyst ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2417003705","title":"Kiora Announces Publication of Phase 1 Study Demonstrating Safety, Tolerability and Anti-Inflammatory Activity of KIO-101 in the Treatment of Inflammation of the Eye","url":"https://stock-news.laohu8.com/highlight/detail?id=2417003705","media":"StreetInsider","top":-1,"share":"https://ttm.financial/m/news/2417003705?lang=en_us&edition=fundamental","pubTime":"2024-03-08 20:02","pubTimestamp":1709899320,"startTime":"0","endTime":"0","summary":"Encinitas, California--(Newsfile Corp. - March 8, 2024) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), (\"Kiora\" or the \"Company\") announced the publication of results from a Phase 1 double-masked study","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.streetinsider.com/dr/news.php?id=22904477","is_publish_highlight":false,"gpt_icon":0},{"id":"2415582206","title":"BRIEF-Kiora Pharmaceuticals Inc Files For Shelf Of Up To 76.5 Million Shares Of Common Stock By Selling Stockholders - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2415582206","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2415582206?lang=en_us&edition=fundamental","pubTime":"2024-02-29 06:43","pubTimestamp":1709160195,"startTime":"0","endTime":"0","summary":"Kiora Pharmaceuticals Inc   :   * KIORA PHARMACEUTICALS INC FILES FOR SHELF OF UP TO 76.5 MILLION SHARES OF COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILINGSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2411180800","title":"Kiora Pharmaceuticals Unveils Updated Investor Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2411180800","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2411180800?lang=en_us&edition=fundamental","pubTime":"2024-02-13 06:33","pubTimestamp":1707777219,"startTime":"0","endTime":"0","summary":"Kiora Pharmaceuticals (KPRX) has released an update. Kiora Pharmaceuticals, Inc. has released an updated investor presentation, which may be showca...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-unveils-updated-investor-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-unveils-updated-investor-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2410031972","title":"Kiora Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2410031972","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2410031972?lang=en_us&edition=fundamental","pubTime":"2024-02-09 19:24","pubTimestamp":1707477840,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KPRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 09, 2024 06:24 ET (11:24 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2410031185","title":"Kiora Pharmaceuticals: Strong Buy Rating on Strategic Partnership and Promising Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2410031185","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2410031185?lang=en_us&edition=fundamental","pubTime":"2024-02-09 19:16","pubTimestamp":1707477414,"startTime":"0","endTime":"0","summary":"Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Kiora Pharmaceuticals (KPRX – Research Report). The associated price target ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kiora-pharmaceuticals-strong-buy-rating-on-strategic-partnership-and-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kiora-pharmaceuticals-strong-buy-rating-on-strategic-partnership-and-promising-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2409013225","title":"Kiora Pharmaceuticals (KPRX) Receives a Buy from Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2409013225","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2409013225?lang=en_us&edition=fundamental","pubTime":"2024-02-07 20:57","pubTimestamp":1707310636,"startTime":"0","endTime":"0","summary":"Maxim Group analyst Michael Okunewitch maintained a Buy rating on Kiora Pharmaceuticals (KPRX – Research Report) yesterday. The company’s shares cl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/kiora-pharmaceuticals-kprx-receives-a-buy-from-maxim-group-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/kiora-pharmaceuticals-kprx-receives-a-buy-from-maxim-group-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2408507807","title":"Kiora Pharmaceuticals Reveals TOI Agreement and Presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2408507807","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2408507807?lang=en_us&edition=fundamental","pubTime":"2024-02-01 18:09","pubTimestamp":1706782184,"startTime":"0","endTime":"0","summary":"Kiora Pharmaceuticals (KPRX) has released an update to notify the public and investors about a regulation fd disclosure. On January 31, 2024, the C...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-reveals-toi-agreement-and-presentation?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-reveals-toi-agreement-and-presentation?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2408951491","title":"Kiora stock soars after hours on deal with Thea Open Innovation","url":"https://stock-news.laohu8.com/highlight/detail?id=2408951491","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2408951491?lang=en_us&edition=fundamental","pubTime":"2024-02-01 08:03","pubTimestamp":1706745790,"startTime":"0","endTime":"0","summary":"Kiora Pharmaceuticals  shares soared 135% in post-market trading Wednesday after the biotech company announced a deal with Thea Open Innovation to commercialize its ophthalmology drug KIO-301 for the treatment of inherited retinal diseases. Under the deal, Kiora granted Thea exclusive rights to develop and commercialize KIO-301 for markets worldwide, excluding Asia. In exchange, Kiora will receive $16M upfront, up to $285M in milestone payments and tiered royalties of up to the low 20% range on net sales. Thea will also reimburse Kiora for R&D expenses.  Thea Open Innovation is a sibling company of French ophthalmology products provider Laboratoires Thea. Kiora said it plans to start a Phase 2 study of the product in the treatment of retinitis pigmentosa in early 2024, with results potentially available in the first half of 2025. Kiora will be responsible for clinical development through Phase 2, with Thea assuming primary responsibility thereafter.   More on Kiora Pharmaceuticals  See","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495408399/image_1495408399.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1495408399/image_1495408399.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4061022-kiora-stock-soars-after-hours-on-deal-with-thea-open-innovation","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.kiorapharma.com","stockEarnings":[{"period":"1week","weight":0.1304},{"period":"1month","weight":-0.0772},{"period":"3month","weight":-0.3201},{"period":"6month","weight":-0.125},{"period":"1year","weight":-0.8215},{"period":"ytd","weight":0.0387}],"compareEarnings":[{"period":"1week","weight":0.0031},{"period":"1month","weight":-0.0266},{"period":"3month","weight":0.0216},{"period":"6month","weight":0.1618},{"period":"1year","weight":0.2378},{"period":"ytd","weight":0.0625}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.108303},{"month":2,"riseRate":0.555556,"avgChangeRate":0.161552},{"month":3,"riseRate":0.111111,"avgChangeRate":-0.134209},{"month":4,"riseRate":0.444444,"avgChangeRate":-0.000799},{"month":5,"riseRate":0.444444,"avgChangeRate":-0.071132},{"month":6,"riseRate":0.125,"avgChangeRate":-0.191937},{"month":7,"riseRate":0.125,"avgChangeRate":-0.199537},{"month":8,"riseRate":0.222222,"avgChangeRate":-0.123001},{"month":9,"riseRate":0.444444,"avgChangeRate":-0.017503},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.01988},{"month":11,"riseRate":0.444444,"avgChangeRate":0.114993},{"month":12,"riseRate":0.333333,"avgChangeRate":0.057855}],"exchange":"NASDAQ","name":"Kiora Pharmaceuticals","nameEN":"Kiora Pharmaceuticals"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Kiora Pharmaceuticals(KPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Kiora Pharmaceuticals(KPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Kiora Pharmaceuticals,KPRX,Kiora Pharmaceuticals股票,Kiora Pharmaceuticals股票老虎,Kiora Pharmaceuticals股票老虎国际,Kiora Pharmaceuticals行情,Kiora Pharmaceuticals股票行情,Kiora Pharmaceuticals股价,Kiora Pharmaceuticals股市,Kiora Pharmaceuticals股票价格,Kiora Pharmaceuticals股票交易,Kiora Pharmaceuticals股票购买,Kiora Pharmaceuticals股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Kiora Pharmaceuticals(KPRX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Kiora Pharmaceuticals(KPRX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction